IQVIA (NYSE:IQV) Releases FY24 Earnings Guidance

IQVIA (NYSE:IQV) issued an update on its FY24 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $11.10-11.20 for the period, compared to the consensus estimate of $11.19. The company issued revenue guidance of $15.35-15.40 billion, compared to the consensus revenue estimate of $15.46 billion. IQVIA also updated its FY 2024 guidance to 11.100-11.200 EPS.

Wall Street Analyst Weigh In

IQV has been the subject of several recent research reports. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price target for the company. Deutsche Bank Aktiengesellschaft reduced their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price target on shares of IQVIA in a report on Friday. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Finally, Barclays lowered their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $261.24.

IQVIA Price Performance

NYSE IQV traded up $3.34 during trading on Friday, hitting $209.16. 1,791,887 shares of the stock traded hands, compared to its average volume of 1,125,496. The company has a market capitalization of $38.13 billion, a P/E ratio of 27.45, a price-to-earnings-growth ratio of 2.01 and a beta of 1.51. IQVIA has a 12-month low of $181.03 and a 12-month high of $261.73. The firm has a 50-day simple moving average of $234.31 and a 200-day simple moving average of $229.74. The company has a quick ratio of 0.85, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.